Nonetheless, the effectiveness of Angiotensin receptor (ATR) treatment is under debate as LIFE, ACCESS and MOSES trials demonstrated a decrease in the frequency of stroke after AT1R blockade (Dahlof et al., 2002; Schrader et al., 2003, 2005), while such treatment failed to show beneficial effects in other trials (Sandset et al., 2011). The gene discussed is AGTR1; the disease is stroke disorder.